Edition:
United States

Collplant Holdings Ltd (CLGN.OQ)

CLGN.OQ on NASDAQ Stock Exchange Capital Market

4.55USD
18 Jan 2019
Change (% chg)

$-0.17 (-3.60%)
Prev Close
$4.72
Open
$4.75
Day's High
$4.75
Day's Low
$4.55
Volume
300
Avg. Vol
4,852
52-wk High
$10.19
52-wk Low
$3.13

Latest Key Developments (Source: Significant Developments)

Collplant Reports Q1 Non-GAAP Loss Per Share $0.01
Thursday, 24 May 2018 05:50am EDT 

May 24 (Reuters) - Collplant Holdings Ltd ::COLLPLANT REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q1 REVENUE ILS 779,000.Q1 NON-GAAP LOSS PER SHARE $0.01.  Full Article

CollPlant Q4 Revenue Rose 375 Percent To ILS 952,000
Wednesday, 21 Mar 2018 06:45am EDT 

March 21 (Reuters) - Collplant Holdings Ltd ::COLLPLANT REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q4 REVENUE ROSE 375 PERCENT TO ILS 952,000.Q4 LOSS PER SHARE $0.01.  Full Article

CollPlant receives innovation authority approval for R&D Program
Monday, 30 Oct 2017 10:04am EDT 

Oct 30 (Reuters) - Collplant Holdings Ltd :Says received Ministry Of Economy Innovation Authority's approval for Collplant's research and development program for 2017​.  Full Article

Collplant Holdings Ltd signs a new, exclusive distributor agreement in Turkey
Monday, 22 May 2017 09:15am EDT 

May 22 (Reuters) - Collplant Holdings Ltd : :Collplant Holdings Ltd - signed a new, exclusive distributor agreement in Turkey to market Vergenix FG, for treatment of chronic wounds.Collplant Holdings Ltd - market potential for treatment of chronic wounds in Turkey is estimated at in excess of 400,000 procedures annually.  Full Article

Collplant Holdings reports positive results from post-marketing surveillance of Vergenix FG
Tuesday, 11 Apr 2017 11:47am EDT 

Collplant Holdings Ltd : Announce positive results from post-marketing surveillance of company's advanced wound care product, Vergenix FG . As part of surveillance, co monitored 10 patients following a single treatment with Vergenix FG in hospitals in Italy, Switzerland .Study showed 5 weeks post treatment, patients displayed average wound closure rate of 80%, with no observed safety/ tolerability issues.  Full Article

Collplant provides commercial and operational update
Thursday, 30 Mar 2017 06:00am EDT 

Collplant Holdings Ltd : Collplant provides commercial and operational update .Pursuing joint ventures with international companies to further advance Bioink in specific indications in 2017.  Full Article

No consensus analysis data available.